Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Odesivimab

Catalog #:   DVV03602 Specific References (18) DATASHEET
Host species: Human
Isotype: IgG1, kappa
Applications: Research Grade Biosimilar
Expression system: Mammalian Cells
Overview

Catalog No.

DVV03602

Expression system

Mammalian Cells

Species reactivity

Zaire ebolavirus (ZEBOV)

Host species

Human

Isotype

IgG1, kappa

Clonality

Monoclonal

Target

Envelope glycoprotein, GP1,2, GP, Shed GP, GP1,2-delta, GP1, GP2, GP

Concentration

2.53 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q05320

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

REGN-3470-3471-3479, REGN-3470/REGN-3471/REGN-3479, REGN-EB3, REGNEB3, Inmazeb (atoltivimab, maftivimab, odesivimab-ebgn), CAS: 2135632-30-1

Clone ID

Odesivimab

Data Image
  • SDS-PAGE
    SDS PAGE for Odesivimab
  • SEC-HPLC
    The purity of this product is >95% as determined by SEC-HPLC.
References

Atoltivimab, Maftivimab, and Odesivimab-ebgn, PMID: 33354710

REGN-EB3: First Approval, PMID: 33432551

Atoltivimab/maftivimab/odesivimab (Inmazeb) combination to treat infection caused by Zaire ebolavirus, PMID: 34405205

Inmazeb, PMID: 33497162

Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma, PMID: 34335620

Structure of the Inmazeb cocktail and resistance to Ebola virus escape., PMID:36708708

A drug-disease model for predicting survival in an Ebola outbreak., PMID:35895082

Effects of therapies for Ebola virus disease: a systematic review and network meta-analysis., PMID:35803293

Antibody Use during an Outbreak of Ebola Virus Disease in the Democratic Republic of Congo, 2020., PMID:35320651

A systematic review of Ebola virus disease outbreaks and an analysis of the efficacy and safety of newer drugs approved for the treatment of Ebola virus disease by the US Food and Drug Administration from 2016 to 2020., PMID:35085865

Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development., PMID:35082794

Identification and Characterization of a Novel Single Domain Antibody Against Ebola Virus., PMID:34632543

Post-exposure prophylaxis following high-risk contact with Ebola virus, using immunotherapies with monoclonal antibodies, in the eastern Democratic Republic of the Congo: an emergency use program., PMID:34587535

A computational overview on phylogenetic characterization, pathogenic mutations, and drug targets for Ebola virus disease., PMID:34563987

Atoltivimab/maftivimab/odesivimab (Inmazeb) combination to treat infection caused by Zaire ebolavirus., PMID:34405205

Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma., PMID:34335620

REGN-EB3: First Approval., PMID:33432551

Atoltivimab, Maftivimab, and Odesivimab-ebgn., PMID:33354710

Datasheet

Document Download

Research Grade Odesivimab.pdf

 

$ 328
Product specifications
100 μg 328 1 mg 1314

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Odesivimab [DVV03602]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only